Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Pituitary Neoplasms 7Neuroendocrine Tumors 6Carcinoid Tumor 5Acromegaly 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Gastro-enteropancreatic neuroendocrine tumor 3Pituitary ACTH Hypersecretion 2Neoplasms 2Neoplasm Metastasis 2Nelson Syndrome 2Multiple Myeloma 2Liver Neoplasms 2Growth Disorders 2Gigantism 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Hepatocellular 2ACTH Syndrome, Ectopic 2Uveal Melanoma 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Sarcoma, Synovial 1Prolactinoma 1Prolactin-Producing Pituitary Tumor 1Primary Inoperable Thymoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Pancreatic Fistula 1Neuroectodermal Tumors, Primitive 1

Interventions

Everolimus 9Temozolomide 7Sunitinib 7Specimen Handling 4Octreotide 4Magnetic Resonance Spectroscopy 4Fluorouracil 4Capecitabine 4lutetium Lu 177 dotatate 3Leucovorin 3sargramostim 2montanide ISA 51 2incomplete Freund's adjuvant 2cabozantinib 2Thalidomide 2Streptozocin 2Sorafenib 2Oxaliplatin 2Irinotecan 2Injections 2Endoscopic Ultrasound-Guided Fine Needle Aspiration 2Doxorubicin 2Cytoreduction Surgical Procedures 2Colony-Stimulating Factors 2Bevacizumab 2surufatinib 1sapanisertib 1recombinant interferon alpha 2b-like protein 1pentetreotide 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × pasireotide × Clear all
NCT00804336 2016-10-19

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
22 enrolled
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡